Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals is supported by a highly durable cystic fibrosis franchise that generated $3.27B in Q3 revenue and nearly $12B in 2025, with Alyftrek adoption, younger-patient expansion, and broad reimbursement helping sustain growth while patent protection extends into at least the late 2030s. Beyond CF, the company is diversifying with Casgevy, Journavx, and Palsonify, and it raised FY26 total revenue guidance to $13.15-13.25B while reiterating combined Journavx + Casgevy sales of more than $500MM. Its positive outlook is further reinforced by a deep late-stage pipeline, including povetacicept’s Nov. 30 PDUFA, inaxaplin, and diabetes cell-therapy programs, which could extend Vertex’s revenue base well beyond CF.

Vertex Pharmaceuticals is vulnerable to a negative thesis because its valuation depends heavily on continued cystic fibrosis leadership while Alyftrek adoption, CF pricing, and competition could all pressure revenue and margins. The pipeline does not fully offset that concentration risk, as negative Pove data in IgAN, delays in the renal franchise, or safety issues across programs such as povetacicept, suzetrigine, and inaxaplin could materially reduce long-term growth and erode pricing power. Lower uptake in Journavx and Alyftrek would further weaken diversification efforts, and the downside scenario points to a DCF-based valuation of $425.